Medicines Regulator Launches Probe into UK Peptide Clinics Over Health Claims
The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated an investigation into whether clinics across the United Kingdom are violating legal standards by promoting unregulated and experimental peptide therapies. This development follows an exclusive Guardian investigation that uncovered multiple clinics making potentially unlawful assertions about the benefits of these treatments.
Surge in Interest and Lack of Evidence
In recent years, there has been a significant increase in interest surrounding experimental peptides, which are administered via injection. These substances are marketed by sellers, influencers, and some medical professionals as solutions for a range of issues, including anti-ageing, weight loss, and injury recovery. However, scientific evidence supporting such health and wellness claims in humans remains scarce, with most studies conducted on animals or at the cellular level.
The MHRA has explicitly stated that clinics are not allowed to make medicinal claims for the peptide treatments they offer. An agency spokesperson emphasized, "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012. The MHRA will take action against clinics which are identified as breaching the legal requirements."
Guardian Investigation Uncovers Widespread Claims
The Guardian's investigation identified several clinics operating in the UK that provide a variety of unregulated, experimental peptides while making numerous claims about their benefits on their websites. For instance, one clinic listed on top Google search results promoted peptides like Cortexin for "neuroprotection and cognitive enhancement," BPC-157 for "tissue repair and recovery from injuries," and Thymosin Alpha to "boost immune function." The MHRA confirmed that such websites were making impermissible medicinal claims. After being contacted by the Guardian, the clinic removed these assertions from its site.
Another prominent clinic acknowledged on its website that peptides lack large clinical trials and have limited human evidence. Despite labeling them as "research only," it advertised seven named peptides with specified "results duration" and prices, charging £350 per month for a single peptide and £450 for two, available in vials with syringes or pre-loaded injection pens for an additional fee.
Consultations Reveal Experimental Nature and Risks
During a free consultation with one clinic, a Guardian reporter was informed that most peptide research is pre-clinical and some peptides remain highly experimental. The clinician noted a deficiency in randomised multi-centre clinical trials to assess long-term effects and advised taking breaks of four to eight weeks between usage periods to mitigate risks. Nevertheless, the clinician recommended two peptides—BPC-157 for post-exercise recovery and MOTS-C for energy production and fat reduction—highlighting concerns such as increased cancer risk for certain individuals.
The clinic defended its practices, stating it clearly explained that peptides are not licensed medicines and evidence is largely pre-clinical. It emphasized shared decision-making and balanced information, while a spokesperson pointed out that many people access peptides through unregulated channels without clinical oversight.
Regulatory Framework and Future Actions
Peptides are short chains of amino acids, some naturally occurring in the body, like insulin. While approved prescription weight-loss drugs such as Wegovy and Mounjaro use synthetic peptides, many others on the market are experimental and have not undergone rigorous regulatory scrutiny.
Lynda Scammell, head of borderline products at the MHRA, clarified, "Peptide products may be sold as cosmetics, supplements, and medicines, depending on their intended purpose. We determine whether a product is a medicine on a case-by-case basis, considering factors like its effect on the body and usage. Claims of 'research purposes' are disregarded if used to evade medicines regulations, and we will take appropriate action against unauthorised medicines."
The MHRA's investigation underscores ongoing concerns about the safety and efficacy of peptide therapies, urging caution among consumers and stricter enforcement of legal standards in the healthcare sector.
